Bionano Genomics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M |
| Cost of revenue | $15.3M | $30.4M | $26.6M | $21.9M | $14.1M |
| Selling, general & administrative | $35.1M | $51.9M | $92.8M | $88.6M | $58.5M |
| Research and development | $11.4M | $24.8M | $54.0M | $49.0M | $22.5M |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M |
| Interest expense | — | — | $5.1M | $298,000 | $927,000 |
| Pretax income | -$26.3M | -$112.0M | -$232.4M | -$130.7M | -$78.2M |
| Income tax expense | $67,000 | $33,000 | $62,000 | $1.9M | -$5.7M |
| Net income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M |
| Balance Sheet | |||||
| Cash and equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M |
| Current assets | $45.4M | $39.5M | $140.1M | $157.3M | $272.4M |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M |
| Current liabilities | $22.9M | $37.3M | $100.0M | $35.9M | $21.8M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M |
| Stockholders' equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M |
| Depreciation and amortization | $9.5M | $14.0M | $13.7M | $9.6M | $3.4M |
| Stock-based compensation | $4.5M | $9.7M | $15.2M | $22.4M | $9.7M |
| Capital expenditure | — | $0 | $6,000 | $90,000 | $0 |
| Free cash flow | — | -$68.9M | -$125.2M | -$124.9M | -$71.9M |
| Impairments | $0 | $19.7M | $77.3M | $0 | $0 |
Shares outstanding 11.5M · Free float 50.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.